Company Description
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases.
The company’s technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging.
Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults.
It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation.
The company was incorporated in 2015 and is based in Richmond, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Sep 26, 2024 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 64 |
| CEO | Kristen Fortney |
Contact Details
Address: 1445A South 50th Street Richmond, California 94804 United States | |
| Phone | 510 806 1445 |
| Website | bioagelabs.com |
Stock Details
| Ticker Symbol | BIOA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001709941 |
| CUSIP Number | 09077V100 |
| ISIN Number | US09077V1008 |
| Employer ID | 47-4721157 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kristen Fortney Ph.D. | Co-Founder, Chief Executive Officer, President, Treasurer, Secretary and Director |
| Dr. Eric Morgen M.D. | Co-Founder, Chief Operating Officer and Director |
| Dr. Paul D. Rubin M.D. | Chief Medical Officer and Executive Vice President of Research |
| Dr. Dov A. Goldstein M.B.A., M.D. | Chief Financial Officer |
| Rusty Montgomery Ph.D. | Senior Vice President of Research |
| Julie Gammelgard | Senior Vice President of People |
| Dr. Peng Leong M.B.A., Ph.D. | Chief Business Officer and Therapeutic Area Head of Brain Aging |
| BJ Sullivan Ph.D. | Chief Strategy Officer |
| Ann C. Neale RN BSN | Chief Development Officer |
| Patrick Martin M.D. | Senior Vice President of Clinical Science |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 4, 2025 | 144 | Filing |
| Dec 4, 2025 | 8-K | Current Report |
| Nov 6, 2025 | 10-Q | Quarterly Report |
| Nov 6, 2025 | 8-K | Current Report |
| Nov 5, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Nov 5, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Oct 2, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 2, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 14, 2025 | SCHEDULE 13G | Filing |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |